The largest prostate cancer screening trial in more than 20 years has expanded to reach Black men, the group at highest risk from the disease. TRANSFORM, a 60-million-pound trial led by Professor Hashim Ahmed at Imperial College London, began recruiting in November 2025 to test new screening methods against the current NHS pathway. The first men have now been tested at a diagnostic centre in Ealing. Stage one will enrol 16,000 men and is expected to finish in December 2027, before a much larger second stage of up to 500,000 men begins in early 2028. In June 2026 the government announced up to 18 million pounds of extra funding so that all eligible Black men can be invited to the second stage. Black men face double the risk of developing and dying from prostate cancer. The UK National Screening Committee decided in June 2026 against population-wide screening, but men aged 45 to 61 with BRCA gene mutations will now be offered screening every two years.
What the Evidence Shows
Prostate cancer is now the most common cancer in Britain, with more than 63,000 men diagnosed each year, over 12,000 deaths, and cases up 42 percent in a decade. Screening is difficult because the PSA blood test produces many false alarms. Cancer Research UK figures show that of 1,000 men screened between the ages of 50 and 60, about 100 have a positive PSA test, 34 go on to have a biopsy, and 28 are diagnosed with cancer, yet only two lives are saved while 20 men are overdiagnosed and 12 receive treatment they do not need. TRANSFORM aims to find a combination of tests that catches aggressive cancers early without that harm, and it has a target that one in ten participants will be Black. If stage one succeeds, screening could begin in as little as two years. Reporting and analysis from sources such as The Lancet track the same developments, and specialists following the TRANSFORM prostate cancer screening trial say the direction is now consistent across independent lines of evidence.
The Wider Context
Equity runs through every discussion of the TRANSFORM prostate cancer screening trial. Interventions that require apps, fees or free weekday afternoons reliably reach the people who need them least, so the programmes earning praise are those designed around clinics, workplaces and community venues that already serve everyone. Evaluation reports now publish uptake by income and region as a matter of routine.
What Happens Next
The practical takeaway on the TRANSFORM prostate cancer screening trial is deliberately unglamorous: it works best as part of ordinary, well-delivered care rather than as a standalone fix. Health services are planning on that basis, building the referral routes and follow-up that turn a promising result into population benefit. The gains arrive slowly and then, in the statistics, unmistakably. You can follow related developments in our coverage of health.
It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.